| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg | |||
| 50mg | |||
| Other Sizes |
Iotalamic acid (Methalamic acid; MI216; Iothalamic acid; MI-216), a bis-benzylidine piperidon analog, can be used as a contrast medium in diagnostic radiology with properties similar to those of diatrizoic acid. It is used primarily as its sodium and meglumine salts.
| ADME/Pharmacokinetics |
Absorption, Distribution and Excretion
Kidney accumulation is rapid; in most cases, maximum contrast density is reached in the renal calyces and pelvis approximately 3 to 8 minutes after injection. Patients with impaired renal function typically require a longer time to achieve diagnostic contrast. After intravascular injection, Conjugate rapidly reaches the kidneys via the circulatory system and is excreted unchanged in the urine via glomerular filtration. The liver and small intestine are the primary alternative routes of excretion. In patients with severe renal impairment, the amount of contrast agent excreted into the small intestine via the gallbladder increases dramatically. Biological Half-Life In patients with normal renal function, the α-half-life and β-half-life of Conjugate are approximately 10 minutes and 90 minutes, respectively. |
|---|---|
| Toxicity/Toxicokinetics |
Protein Binding
Iodotalate has a poor binding affinity to serum albumin. |
| Additional Infomation |
Iostatin is an organic molecular entity. Iostatin is an iodine-containing organic anion used as a diagnostic contrast agent. Iostatin is a radiological contrast agent. The mechanism of action of iostatin is as an X-ray contrast agent. Iostatin is an ionic triiodobenzoate used as a contrast agent in diagnostic imaging. Like other organic iodine compounds, iostatin blocks X-rays, appearing opaque on X-ray film, thus enhancing the visibility of structures and organs during angiography, arteriography, arthrography, cholangiography, and computed tomography (CT). Iostatin is a diagnostic radiological contrast agent with properties similar to iodopantoic acid. It is primarily used in its sodium and meglumine salt forms (iostatin meglumine). See also: Iostatin meglumine (salt form). Sodium iostatin (salt form).
Drug Indications Conjugation is indicated for excretory urography, cerebral angiography, peripheral arteriography, venography, arthrography, direct cholangiography, endoscopic retrograde cholangiopancreatography, contrast-enhanced CT images of the brain, cranial CT angiography, digital subtraction angiography of veins, and digital subtraction angiography of arteries. Conjugation can also be used to enhance CT scan images to detect and evaluate lesions of the liver, pancreas, kidneys, abdominal aorta, mediastinum, abdominal cavity, and retroperitoneal space. |
| Molecular Formula |
C₁₁H₉I₃N₂O₄
|
|---|---|
| Molecular Weight |
613.91
|
| Exact Mass |
613.77
|
| CAS # |
2276-90-6
|
| Related CAS # |
Iotalamic acid-d3;928623-31-8
|
| PubChem CID |
3737
|
| Appearance |
White to off-white solid powder
|
| Density |
2.54 g/cm3
|
| Boiling Point |
520.2ºC at 760 mmHg
|
| Melting Point |
285ºC
|
| Flash Point |
268.4ºC
|
| LogP |
2.98
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
20
|
| Complexity |
421
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
UXIGWFXRQKWHHA-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C11H9I3N2O4/c1-3(17)16-9-7(13)4(10(18)15-2)6(12)5(8(9)14)11(19)20/h1-2H3,(H,15,18)(H,16,17)(H,19,20)
|
| Chemical Name |
3-acetamido-2,4,6-triiodo-5-(methylcarbamoyl)benzoic acid
|
| Synonyms |
Methalamic acidIotalamic acid MI 216 MI216Iothalamic acid MI-216
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ≥ 25 mg/mL (~40.72 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (3.39 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (3.39 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (3.39 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.6289 mL | 8.1445 mL | 16.2890 mL | |
| 5 mM | 0.3258 mL | 1.6289 mL | 3.2578 mL | |
| 10 mM | 0.1629 mL | 0.8145 mL | 1.6289 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
